Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avalyn PharmaAVLN -4.91%12 EV-to-FCF is -18.87 as of Sep. 18, 2026. GuruFocus rates AVLN with a GF Score™ of 12/100. Among 330 Biotechnology companies, Avalyn Pharma ranks worse than 303030% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Avalyn Pharma's Enterprise Value is $1,067.38 Mil.
Avalyn Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was $-56.55 Mil. Therefore, Avalyn Pharma's EV-to-FCF for today is -18.87.
The historical rank and industry rank for Avalyn Pharma's EV-to-FCF or its related term are showing as below:
AVLN'
s EV-to-FCF Range Over the Past 10 Years
Min: -22.62 Med: 0 Max: 0
Current: -18.87
AVLN's EV-to-FCF is ranked worse than 100% of 330
companies
in the Biotechnology industry
Industry Median: 14.365
vs AVLN: -18.87
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Avalyn Pharma's PE Ratio (TTM) for today is calculated as:
Avalyn Pharma's share price for today is $31.76.
Avalyn Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.259.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Avalyn Pharma EV-to-FCF Related Terms
Avalyn Pharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Avalyn Pharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalyn Pharma EV-to-FCF Chart
Avalyn Pharma Annual Data
Trend
Dec24
Dec25
EV-to-FCF
0.00
0.00
Avalyn Pharma Quarterly Data
Mar25
Jun25
Mar26
Jun26
EV-to-FCF
0.00
0.00
0.00
0.00
AVLN vs LBRX, LTGO, NVAX: EV-to-FCF Comparison
For the Biotechnology subindustry, Avalyn Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avalyn Pharma EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avalyn Pharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Avalyn Pharma's EV-to-FCF falls into.
Avalyn Pharma's current Enterprise Value is $1,067.38 Mil.
Avalyn Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-56.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalyn Pharma (AVLN) has a EV-to-FCF of -18.87 as of Sep. 18, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Avalyn Pharma and its competitors. According to the industry distribution chart, Avalyn Pharma ranks #999999 out of 330 companies in the Biotechnology industry.
Is Avalyn Pharma's EV-to-FCF too high?
Avalyn Pharma's current EV-to-FCF is -18.87. Based on the distribution chart, Avalyn Pharma ranks #999999 out of 330 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Avalyn Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Avalyn Pharma's EV-to-FCF compare to LBRX and LTGO?
According to the Biotechnology industry distribution chart, Avalyn Pharma ranks #999999 out of 330 companies for EV-to-FCF. This places Avalyn Pharma in the lower half of its industry. The industry median EV-to-FCF is 14.37. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.37, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Avalyn Pharma and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avalyn Pharma's current EV-to-FCF is -18.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalyn Pharma stock overvalued right now?
Avalyn Pharma (AVLN) has a current EV-to-FCF of -18.87. The current EV-to-FCF is -18.87. Avalyn Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Avalyn Pharma (AVLN), the current EV-to-FCF is -18.87 as of Sep. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
12GF Score
Get the complete analysis for AVLN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVLN has been successfully added to your 
